Stock OPTI OPTIBIOTIX HEALTH PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials OptiBiotix Health Plc

Equities

OPTI

GB00BP0RTP38

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:03 2024-06-28 EDT 		5-day change 1st Jan Change
16 GBX 0.00% Intraday chart for OptiBiotix Health Plc 0.00% -40.19%
06-28 OptiBiotix Health Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
06-21 OptiBiotix says probe finds Slimbiome reduces hunger feeling AN

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 77.1 56.39 51.01 40.45 12.08 24.39
Enterprise Value (EV) 1 75.77 56.66 50.91 39.26 11.03 23.76
P/E ratio -39 x -28.7 x 9.56 x 7.02 x 4.77 x -11.9 x
Yield - - - - - -
Capitalization / Revenue 150 x 82 x 33.5 x 18.3 x 26.4 x 37.9 x
EV / Revenue 147 x 82.4 x 33.4 x 17.7 x 24.1 x 36.9 x
EV / EBITDA -55.8 x -34.8 x -59 x -36.5 x -4.87 x -15.9 x
EV / FCF -59.8 x - -49.9 x -29.1 x -14.3 x -26.8 x
FCF Yield -1.67% - -2% -3.44% -7% -3.73%
Price to Book 11 x 10.9 x 4.32 x 2.23 x 1.11 x 2.83 x
Nbr of stocks (in thousands) 84,724 85,441 87,941 87,941 91,191 91,191
Reference price 2 0.9100 0.6600 0.5800 0.4600 0.1325 0.2675
Announcement Date 4/29/19 5/28/20 7/9/21 6/27/22 6/23/23 6/28/24
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.5143 0.6876 1.523 2.213 0.457 0.644
EBITDA 1 -1.357 -1.628 -0.8635 -1.077 -2.265 -1.49
EBIT 1 -1.499 -1.829 -1.111 -1.365 -2.489 -1.695
Operating Margin -291.45% -265.97% -72.96% -61.7% -544.64% -263.2%
Earnings before Tax (EBT) 1 -1.947 -2.069 5.71 6.177 2.441 -2.043
Net income 1 -1.919 -1.954 5.802 6.261 2.587 -2.039
Net margin -373.19% -284.24% 380.89% 282.93% 566.08% -316.61%
EPS 2 -0.0233 -0.0230 0.0607 0.0655 0.0278 -0.0224
Free Cash Flow 1 -1.267 - -1.021 -1.351 -0.7716 -0.8864
FCF margin -246.34% - -67% -61.05% -168.85% -137.64%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/29/19 5/28/20 7/9/21 6/27/22 6/23/23 6/28/24
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 0.27 - - - -
Net Cash position 1 1.32 - 0.09 1.19 1.05 0.64
Leverage (Debt/EBITDA) - -0.1666 x - - - -
Free Cash Flow 1 -1.27 - -1.02 -1.35 -0.77 -0.89
ROE (net income / shareholders' equity) -26.8% - 68.9% 41.7% 17.8% -20.6%
ROA (Net income/ Total Assets) -11.9% - -6.78% -5.04% -9.82% -10.1%
Assets 1 16.08 - -85.6 -124.2 -26.35 20.16
Book Value Per Share 2 0.0800 0.0600 0.1300 0.2100 0.1200 0.0900
Cash Flow per Share 2 0.0200 0.0100 0.0100 0.0200 0.0100 0.0100
Capex 1 0 - - - - -
Capex / Sales 0.57% - - - - -
Announcement Date 4/29/19 5/28/20 7/9/21 6/27/22 6/23/23 6/28/24
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
OPTIBIOTIX HEALTH PLC Stock OptiBiotix Health Plc
-40.19% 19.8M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. OPTI Stock
  4. Financials OptiBiotix Health Plc